Low Dose Atropine for Symptomatic Vitreous Floaters

Launched by JEANETTE DU · Dec 8, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a potential new treatment for people who have bothersome vitreous floaters—those little spots or lines that can drift around in your vision. The researchers want to see if a low dose of atropine (a medication) can help reduce the annoyance caused by these floaters. They will measure how effective the treatment is by using a specific questionnaire that asks about patients' vision-related quality of life.

To be eligible for this study, participants must be adults who have been diagnosed with acute posterior vitreous detachment, a condition that can lead to floaters. However, people with certain eye problems, such as bleeding in the eye or a history of specific eye surgeries, won't be able to join. The trial is currently not recruiting participants yet, but once it starts, those who qualify can expect to receive the medication and complete follow-up assessments to see how well it works for them.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients within Prism Vision Group with ICD diagnosis of acute posterior vitreous detachment and none of the ocular comorbidities listed as exclusion criteria will be screened as potential study participants.
• Exclusion Criteria:
• • Patients with vitreous hemorrhage, other significant media opacity or vitreoretinal pathology, or history of pars plana vitrectomy will be excluded.